— Know what they know.
Not Investment Advice

ARQT NASDAQ

Arcutis Biotherapeutics, Inc.
1W: -0.2% 1M: +18.2% 3M: +11.9% YTD: +9.7% 1Y: +58.4% 3Y: +949.8% 5Y: +51.0%
$31.68
-0.13 (-0.41%)
After Hours: $31.87 (+0.19, +0.60%)
Weekly Expected Move ±9.8%
$25 $28 $31 $34 $37
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Buy · Power 78 · $4.0B mcap · 110M float · 2.04% daily turnover · Short 42% of daily vol
Credit Risk of going bust: lower than 69% of companies Debt: 2.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.11 (down 99.7%), Arcutis Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $114.1M against a stock market value of $4.00B.
Distance to default 7.38 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $57.9M (short-term plus half of long-term), stock volatility 56.8%; Altman Z'' -2.01. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

📊 Key Metrics

TTM
$464M
Revenue
+76.1% YoY
$29M
Net Income
+130.6% YoY
$39M
Free Cash Flow
+154.9% YoY
91.6%
Gross Margin
12.7%
Op. Margin
11.6%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE15.9%
ROA6.8%
ROIC34.7%

Valuation

P/E143.7
P/B18.8
EV/EBITDA77.9

Leverage

Debt/Equity0.52
Current Ratio2.92
Interest Cov.3.0x

Quality Scores

Piotroski F7/9
Altman Z6.71
Beneish M-2.13

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms